Robert Nelsen
Director at City Therapeutics; Director at Vir Biotechnology; Director at Prime Medicine. Based in Cambridge, Massachusetts.
- Rank
- 13438th of 14,644
- Companies held
- 3
- Largest holding
- VIR, 98.5% of total
- Latest SEC filing
- Oct 19, 2026
- Listed but not counted
- $466M
What the $5.6M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Vir Biotechnology VIR Common Stock | Directly | 584,148 | $8.87 | $5.2M | 93.1% | Form 4, May 30, 2024 |
| Vir Biotechnology VIR Common Stock | Indirectly (see filing footnote) | 33,893 | $8.87 | $301K | 5.4% | Form 4, May 30, 2024 |
| Prime Medicine PRME Common Stock | Indirectly (see filing footnote) | 16,080 | $3.84 | $62K | 1.1% | Form 4, Aug 1, 2025 |
| Sana Biotechnology SANA Common Stock | Indirectly (see filing footnote) | 12,500 | $1.74 | $22K | 0.4% | Form 4, Feb 8, 2024 |
| Sana Biotechnology SANA Common Stock | Directly | 1,353 | $1.74 | $2K | 0.0% | Form 4, Feb 8, 2024 |
Share counts are the amounts Robert Nelsen reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Robert Nelsen's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| City Therapeutics CTY Common Stock | Through ARCH Venture Fund XII, L.P. Held by a company or fund the insider manages | 13,692,507 | $18.35 | $251M | — | Form 4, Oct 19, 2026 |
| Vir Biotechnology VIR Common Stock | Through ARCH Venture Fund IX Overage, L.P. Held by a company or fund the insider manages | 7,290,655 | $8.87 | $64.7M | — | Form 4, May 30, 2024 |
| Vir Biotechnology VIR Common Stock | Through ARCH Venture Fund IX, L.P. Held by a company or fund the insider manages | 5,626,008 | $8.87 | $49.9M | — | Form 4, May 30, 2024 |
| Prime Medicine PRME Common Stock | Through ARCH Venture Fund XII, L.P. Held by a company or fund the insider manages | 6,230,300 | $3.84 | $23.9M | — | Form 4, Aug 1, 2025 |
| Prime Medicine PRME Common Stock | Through ARCH Venture Fund X Overage, L.P. Held by a company or fund the insider manages | 6,128,297 | $3.84 | $23.5M | — | Form 4, Aug 1, 2025 |
| Sana Biotechnology SANA Common Stock | Through ARCH Venture Fund X, L.P. Held by a company or fund the insider manages | 12,446,022 | $1.74 | $21.7M | — | Form 4, Feb 8, 2024 |
| Sana Biotechnology SANA Common Stock | Through AVP IX LP Held by a company or fund the insider manages | 10,667,387 | $1.74 | $18.6M | — | Form 4, Feb 8, 2024 |
| Lyell Immunopharma LYEL Common Stock | ARCH Venture Fund IX Overage, L.P. Held by a company or fund the insider manages | 910,318 split-adjusted | $13.58 | $12.4M | — | Form 4, Jun 14, 2024 |
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 13435 | Dinkar S. Bhatia See Remarks, X-Energy. Rockville, MD | $5.6M |
| 13436 | Richard F. Zannino Director, People. New York, NY | $5.6M |
| 13437 | Mark A. Petrarca Senior Vice Pres. - H.R. & P.A, A. O. Smith. Milwaukee, WI | $5.6M |
| 13438 | Robert Nelsen Director, City Therapeutics. Cambridge, MA | $5.6M |
| 13439 | Michael Carlet Chief Financial Officer, Resideo Technologies. Melville, NY | $5.6M |
| 13440 | Vincent Campagnoli EVP, Technology & Operations, Raymond James Financial. St. Petersburg, FL | $5.6M |
| 13441 | Susan E. Arnold Director, The Walt Disney. Burbank, CA | $5.6M |
Other City Therapeutics insiders
All CTY insiders- John Maraganore$32.8MDirector. #1983 overall
- Andrew C. Orth$19.5MPresident & CEO. #5296 overall
- Sebastian Trousil$9.8MChief Operating Officer. #8924 overall
Questions
How much stock does Robert Nelsen own?
Robert Nelsen holds $5,567,875 in listed stock based on SEC filings and current prices, mostly Vir Biotechnology (VIR). That ranks 13438th on the Stock Rich List.
Is this Robert Nelsen's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Robert Nelsen last buy or sell stock?
The most recent open-market trade on file is a purchase of 170,000 CTY shares on Oct 19, 2026 at $18.00.